New study probes Glucagon's hidden role in blood sugar after gastric bypass
NCT ID NCT07212868
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This study looks at how the hormone glucagon influences blood sugar in people who have had bariatric surgery and those who haven't. Researchers will use an experimental drug called REMD-477 to block glucagon and measure changes in glucose metabolism. The goal is to better understand why some people develop blood sugar problems after surgery. The study involves 150 adults aged 18 to 65 who are non-diabetic.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-DIABETIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Diabetes Institute - University Health System
RECRUITINGSan Antonio, Texas, 78207, United States
Contact
Contact
-
University of Texas San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REMD-477 (a monoclonal antibody that blocks glucagon) and glucagon infusion
What this could lead to
If successful, this study could help explain why some people develop diabetes after bariatric surgery and point toward new treatments.
What could go wrong
This is an early-phase study with only 150 participants, so results may not apply to everyone. The drug REMD-477 is investigational and not yet FDA-approved.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.